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Abstract 
 
Calmodulin (CaM) is a ubiquitously expressed calcium-binding protein that plays a critical role in cardiac 
physiology.  CaM senses intracellular Ca2+ changes by binding the Ca2+ ion with one of its four calcium-
binding loops, causing a conformational change in the CaM protein structure, and thereby affecting 
CaM’s affinity for its multiple intracellular protein targets.  Since Ca2+ transients rise and fall in the heart 
on a beat-to-beat basis, an understanding of the kinetics of CaM-Ca2+ binding and dissociation events 
are essential for studying how cardiac systems are regulated.  Isolated CaM kinetic experiments have 
described CaM behavior in controlled solutions, but aren’t directly applicable to the protein’s complex 
physiological environment.  We employed site-directed mutagenesis to generate three CaM mutants 
with Threonine to Cysteine substitutions at residues 5, 34, and 44 (T5C, T34C, T44C).  A fluorescent 
probe (IAANS) was covalently linked to the introduced Cysteine residue.  These fluorescent Calmodulin 
proteins have a unique fluorescent behavior that differentiates them from any intrinsic (Tryptophan, 
Phenylalanine, Tyrosine) fluorescent signals.  We demonstrate that two of these proteins (T5C, T34C) 
have fluorescent behavior that closely mimics that of WT CaM in the presence of representative peptide 
fragments of Myosin Light Chain Kinase (RS-20), Neural Nitric Oxide Synthase (nNOS), Calcineurin (CaN), 
and CaM-dependent Kinase II (CKII).  Thus, T5C or T34C CaM labeled with IAANS has unique fluorescent 
properties without drastically affecting the behavior of the CaM protein. These fluorescent proteins give 
researchers the freedom to study CaM kinetic characteristics in the presence of enzymes regulated by 
CaM, allowing for more research with direct relevance to physiological pathways. 
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Engineering a Fluorescent Calmodulin for Use in Complex Models of Cardiac Physiology 
 
Chapter I 
 
 Before every NASA rocket launch, before every clinical drug trial, before every building 
demolition, you can expect one common process.  No matter how much is known about 
projectile motion, pharmacology, dynamite, or otherwise, there is enough room for error that 
scientists are drawn to model systems to make sure that ideas will work full-scale.  So, the 
NASA engineers turn to computer models to judge the feasibility of new rockets.  Doctors have 
animal models to predict the efficacy and safety of a drug in humans.  And, with similar safety 
concerns in mind, a demolition crew can blow up a small model of a building in an empty field 
before they implode the real thing near a bustling metropolis.  Models give scientists an 
opportunity to reduce the scale, complexity, or cost of the real thing, so that they can make 
assessments and adjustments before moving on to more complex tasks. 
 In the realm of biology, model systems become extremely useful.  For example, the 
behavior of a cell in culture can be used to describe the behavior of a tissue, an organ, a system, 
and so forth.  The behavior of a protein in vitro might indicate its function in vivo.  Biology is 
particularly well-suited to be modeled, because we can’t feasibly understand how organisms 
work just by observing them macroscopically.  The essence of the scientific method revolves 
around breaking down problems to their simplest form, eliminating confounding variables, and 
testing specific hypotheses.  However, biological systems are not always amenable to 
experimentation.  If a scientist wanted to examine, for example, the mechanisms underlying 
contractility of the heart, he is confronted with a bevy of ethical concerns.  Rightfully so, living 
things are not to be wastefully expended at the altar of science, unless absolutely necessary to 
test a specific, important hypothesis.   
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Like the NASA engineer or the building demolition crew, the biologist is drawn to model 
systems when designing experiments concerning living systems.  Model systems allow the 
biologist to reduce the complexity of physiological systems, so that he can eliminate 
confounding variables and better understand his data.  A scientist can’t expect to master the 
complexity of the heart by studying the organ intact in animals.  Some reductionism must be 
applied.  To understand the myocardium, he might extract and study a single cardiac myocyte.  
To understand the myocyte, he might analyze the structure and function of a single myosin 
molecule.  It is apparent that a myriad of models systems, all with varying complexity, could be 
designed to understand the function of the heart. 
One player in cardiac function, and the main character of this thesis, is calmodulin 
(CaM).  This small protein is vital for animal and plant life.  CaM translates intracellular calcium 
concentrations into cellular responses.  Like any other facet of biology—or science in general—
researchers are very interested in designing methods and systems for studying the activity of this 
protein.  Some researchers are trained as physiologists, and hope to characterize the protein as it 
relates to the living systems it regulates.  Other researchers are trained as X-ray 
crystallographers, and hope to characterize the calmodulin crystal structure.  Other researchers 
still are protein biochemists, and want to understand how CaM’s amino acid sequence governs 
its function.  Even though all these researchers are studying the same protein, there are still 
unlimited approaches to just this one protein. 
Problem Statement 
In the highly diverse field of calmodulin research, there is a distinct lack of unification 
between simple and complex model systems.  The strategies employed to study isolated CaM in 
solution are not amenable to study CaM bound to a target, and vice versa.  This disjoint prevents 
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fluidity in translating results from isolated CaM experiments into more complex systems of 
cardiac physiology.  For example, a protein biochemist may discover a way of increasing an 
isolated CaM molecule’s sensitivity to calcium.  This is a very exciting proposition for the 
physiologist that works with CaM, because he can potentially use this sensitized protein to affect 
the behavior of cardiac muscle.  Both researchers need a way of tracking CaM’s behavior in their 
own system, a problem most commonly overcome by fluorescence.  The protein biochemist 
would have made his sensitization discovery using intrinsic fluorescence, which is the natural 
fluorescence of amino acids, such as tyrosine or tryptophan.  The physiologist cannot possibly 
follow the intrinsic fluorescence of CaM in more complex systems—there will be tyrosine and 
tryptophan residues in virtually every other protein in his model.  So the physiologist is more 
interested in extrinsic fluorescence, which are prosthetic fluorescent groups covalently bound to 
the CaM molecule.   
The problem is that the protein biochemist’s breakthrough finding might not work in the 
presence of the physiologist’s prosthetic fluorophore.  Conversely, discoveries the physiologist 
might make in a system with extrinsic fluorescence might not be necessarily true for a system 
using just the isolated CaM protein.  In essence, while fluorescence is a common tool for 
studying CaM function, there is a gap between single-molecule and complex model systems.  A 
fluorescence strategy that is functional for both the isolated protein and also in complex systems 
involving multiple proteins would facilitate better translation of in vitro observations to in vivo 
tests of CaM behavior. 
Review of Literature 
Properties of CaM.  It is logical, before discussing the current status of CaM research, to 
acquaint the reader with CaM and its role in the human body.  Calmodulin is essential for animal 
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life, and genomic data suggests that evolutionary pressure has ensured that the calmodulin gene 
is redundant, to avoid lethal recombination events involving the CaM gene (Fischer, et al., 1988).  
This redundancy might also be attributable for a need for more transcriptional real-estate needed 
to express high levels of CaM.   
CaM is a member of the EF-hand family of proteins, which is a structural motif that 
consists of a helix-loop-helix pattern.  CaM has four such loops, each of which binds a calcium 
ion, for a total of four calcium binding loops.  The protein takes on a dumbbell shape in the 
crystal structure, as shown in Figure 1.  Generally speaking, CaM translates intracellular changes 
in the calcium concentration into a cellular response by binding calcium and activating targets 
(Chin & Means, 2000). 
 When CaM binds calcium ions, it undergoes a conformational change, which is the 
method by which it is able to regulate other proteins.  The surface of the CaM molecule is 
generally hydrophilic in the absence of calcium.  Upon binding calcium, CaM exposes a 
hydrophobic pocket, and is able to associate with target proteins.  These targets are extremely 
diverse, and can include phosphatases, kinases, and many other types of enzymes.  Thus, CaM 
doesn’t have an extremely specific binding region; it is instead the calcium sensor for hire, so to 
speak.  By having flexible binding domain, CaM is able to turn on hundreds of different enzymes 
(Vogel, 1994). 
 If the amino acid sequence for each enzyme regulated by CaM were compared to each 
other, one might expect that the CaM-binding region of each enzyme would be very similar.  
This, surprisingly, is not the case.  CaM does not need to bind to a specific amino acid sequence, 
which explains why CaM can be such a ubiquitous regulator of enzymatic activity.  Enzymes 
that bind with CaM have a binding site that is basic and hydrophobic.  This, in combination with 
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CaM’s hydrophobic, methionine rich flexible interior, facilitates a favorable interaction (Vogel, 
1994).  Taking all this into account, it seems reasonable that slight alterations can be made to 
CaM, without necessarily disrupting its ability to be a malleable protein that nonspecifically 
associates with a legion of different targets.  CaM’s plasticity will be a characteristic of great 
importance later in this essay. 
 Current methods for studying CaM using fluorescence.  As mentioned previously, current 
methodology for studying CaM is a segmented field of study.  One sphere of CaM research 
involves intrinsic fluorescence.  This technique is only useful when certain criteria are met.  For 
one, if you’re following the fluorescence of a specific amino acid, such as tyrosine or 
phenylalanine, the more of that amino acid there is in the protein, the more convoluted your 
signal will be.  Figure 2 gives the amino acid sequence of human calmodulin, with residues 
pertinent to this thesis specially indicated.  Notice that calmodulin has eight phenylalanine (F) 
residues, one tyrosine (Y) residue, and zero tryptophan (W) residues.  This relatively low amount 
of fluorescently active amino acids makes CaM an attractive protein to monitor via intrinsic 
fluorescence.  But, this technique can only be taken so far, because once CaM’s binding partners 
are included in experiments, multiple other fluorescently active residues from the new proteins 
will override signals from CaM.  Thus, intrinsic fluorescence cannot easily be used in any system 
where CaM is not the lone protein. 
Without any genetic modifications, naturally occurring, fluorescently active residues can 
be monitored, and the conformational changes that CaM undergoes when binding calcium affect 
the fluorescence of those residues.  Thus, researchers can observe calcium binding by observing 
fluorescence changes.  More specifically, the C-terminal half of the protein, which is the only 
region that has a tyrosine residue, can easily be monitored by selecting for tyrosine fluorescence 
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properties.  Using intrinsic fluorescence, it has been shown that the two domains of CaM—the 
C-terminal half, and the N-terminal half—have separate calcium binding properties.  More 
specifically, the C-terminal domain has a higher affinity for calcium than the N-terminal domain 
(VanScyoc, et al., 2002).  Of particular interest in the VanScyoc study is the regional specificity 
of intrinsic fluorescence.  Meaning, since tyrosine is only expressed in the C-terminal end of the 
protein, it is only sensitive to changes that occur in that half of the protein.  The idea that 
fluorescent probes best report activity in their immediate local environment is a crucial aspect of 
this thesis. 
Intrinsic fluorescence does not necessarily imply that the WT protein must be studied.  It 
instead denotes that the fluorescence source is an amino acid within the protein of interest, not a 
covalently attached fluorophore.  That being said, some genetic modifications have been used to 
better optimize intrinsic fluorescence within CaM.  Instead of taking the fluorescent amino acids 
in a protein for granted, genetic engineering techniques can be used to replace certain amino 
acids.  This is particularly of interest for CaM, because there are no naturally occurring 
tryptophan (W) residues in the CaM sequence.  Thus, by engineering a tryptophan in the place of 
a phenylalanine, a researcher can selectively monitor specific regions of CaM by choosing where 
to insert the tryptophan residue.  This method has been used to elucidate the magnesium and 
calcium binding mechanics of CaM (Tikunova, Black, Johnson, & Davis, 2001). 
When intrinsic fluorescence is used as a detector, however, other proteins can’t be 
included with CaM in the design of more sophisticated experiments.  As detailed earlier, the 
intrinsic fluorescence properties of each participant protein will conflict, yielding convoluted and 
uninterpretable data.  Although it might not have been much concern, the VanScyoc group was 
beginning to run into this problem in a 2006 study.  Their study was interested in the effects of 
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point mutations of the CaM sequence, and how those mutations affected CaM calcium binding 
behavior.  A few point mutations identified in Paramecium that seemed to impart special 
characteristics to CaM regulatory activity were tested in vitro.  Of the dozen or so mutations 
tested, a few showed alterations in the calcium binding properties of the isolated protein.  
However, the other mutations did not show differences in calcium binding when compared to 
control, wild-type (WT) protein.  The end of the study surmises that “some of these mutations 
alter calcium-binding directly, others probably alter CaM-channel association or calcium-
triggered conformational change in the context of a ternary complex with the affected ion 
channel” (VanScyoc, Newman, Sorensen, & Shea, 2006).  In this example, the group is so very 
close to establishing a mechanism for how point mutations in CaM cause differential regulation 
of ion channels in Paramecium.  However, they can only test the in vitro isolated CaM behavior, 
and not their hypothesis about ternary complex formation.  They’ve hit the ceiling of intrinsic 
fluorescence—they can’t follow what CaM is doing in the presence of other proteins, they can 
only test the effects of point mutations on the CaM protein by itself. 
 On the other side of the rift, there is an entirely different field of CaM research that relies 
on extrinsic fluorescence.  Extrinsic fluorescence, unlike intrinsic fluorescence, does not rely on 
the natural absorption or emission properties of the WT protein.  Instead, fluorescently active 
molecules called fluorophores are covalently linked to a protein of interest.  In order for the 
fluorophore to be useful, the fluorescence of the fluorophore needs to change as the 
conformational structure of the protein changes.  Thus, a fluorescent signal change is equal to a 
protein shape change.  In calmodulin’s case, a fluorescent signal change is equal to a binding 
event.  That binding event can be CaM binding with calcium, or CaM binding with a target 
enzyme or peptide. 
Engineering a Fluorescent Calmodulin      10 
 
 One possible method for analyzing CaM conformational changes via extrinsic 
fluorescence utilizes Fluorescence Resonant Energy Transfer (FRET).  FRET techniques usually 
rely on two fluorescent probes being attached to the same protein.  The fluorescence of the 
acceptor molecule is directly related to its distance away from the donor molecule.  As the 
protein changes its conformational shape, the FRET probes move closer or further away, which 
alters the acceptor’s fluorescence.  In the field of CaM research, FRET has been used to analyze 
the characteristics of CaM binding to target proteins.  CaM labeled with a FRET probe system 
was shown to bind to a nitric oxide synthase (NOS) peptide segment with lower affinity than 
CaM binds to the intact holo-enzyme form of NOS.  These results suggest that distal domains of 
CaM target proteins—not just the CaM-binding regions—are involved in the recruitment and 
association with CaM (Spratt, Taiakina, Palmer, & Guillemette, 2008).  A problem with this 
FRET-based approach, however, stems from the size of the FRET fluorophores.  It is unclear 
whether or not FRET molecules can accurately measure the activity of a small protein like CaM 
without altering CaM’s characteristics. 
 Alternatively, FRET probes can also be placed on CaM’s target, rather than CaM itself.  
A study used two different “biosensor” molecules, which were CaM-binding peptides with 
FRET probes attached, to analyze CaM association with a target peptide (Song, Saucerman, 
Bossuyt, & Bers, 2008).  The advantage to this method is that it allows the activity of CaM to be 
measured without directly affecting the CaM protein itself.  However, this fluorescent technique 
cannot be expanded to include other experimental designs—a new biosensor molecule would 
need to be generated for each peptide to be tested.  Since CaM regulates hundreds of enzymes, 
finding a suitable FRET-labeled peptide fragment of each enzyme represents several lifetimes of 
work. 
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 Thus, a major problem with FRET-based approaches to CaM research stems from the 
small size of CaM.  CaM is only 149 amino acids long, while FRET probes are large aromatic-
rich molecules with hefty molecular weights.  Attaching two FRET probes to CaM might 
overwhelm the protein’s ability to move through space and carry out its normal functions.  The 
observation technique probably interferes with the process being observed; there are probably 
better solutions.  In an effort to generate a CaM protein that has relevance in both biochemical 
and physiological model systems, extrinsic fluorescence should be used, but the size of the 
fluorophore must be minimized so that the the natural behavior of CaM is not affected.  
Furthermore, due to the promiscuity of CaM binding, the most effective model system will place 
the fluorophore on CaM itself, and not on a specifically-designed fluorescent CaM target. 
 Small, fluorescent molecules have been used to tag CaM before.  Generally speaking, 
these molecules are usually designed to covalently link with the unique thiol chemistry specific 
to cysteine residues.  Attaching fluorophores to cysteine residues is advantageous because 
cysteine is the only amino acid with a thiol group, allowing for the fluorophore to be introduced 
at very specific attachment points.  However, mammalian CaM does not natively express any 
cysteine residues (see Figure 2).  Plant CaM, such as the CaM found in wheat, does contain a 
cysteine residue.  Taking the location of the cysteine residue for granted, a research group tested 
the effects of fluorescent labeling with four different fluorophores.  They concluded that 
cysteine-bound small fluorophores didn’t noticeably affect CaM’s ability to activate a target 
enzyme (Zot, Aden, Samy, & Puett, 1990).  This particular research is exciting for my study, 
because preliminary evidence already exists that suggests that small fluorescent molecules can be 
introduced into CaM without affecting CaM’s behavior. 
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 There is a missing piece at the junction of the FRET modelers and the plant CaM 
researchers.  An opportunity exists for the ideas that plant calmodulin researchers to be used in 
animal-centric research.  All that’s missing is cysteine residues in mammalian CaM.  If a 
researcher is able to introduce a cysteine residue into the CaM sequence, such as through site-
directed mutagenesis, they would be able to engineer a fluorescent CaM with the fluorophore 
attached wherever they chose to place the cysteine residue.  Finding the best location to 
introduce a cysteine residue into CaM so that it can be studied via small molecule fluorescence is 
the crux of this thesis. 
 Troponin C  fluorescent research.  Before attempting to design a novel fluorescent 
calmodulin by introducing a cysteine residue, then attaching an extrinsic fluorophore, it makes 
sense to see what strategies have worked in proteins similar to CaM.  One similar protein is 
troponin C, another calcium-binding protein of the EF-hand family.  Remember, calmodulin is a 
calcium sensor that is expressed in every animal cell, and is used to regulate hundreds of 
different enzymes.  In contrast, troponin C is a calcium sensor that is specific to striated muscle 
tissue.  Striated muscles include cardiac and skeletal muscles.  Just like calmodulin, troponin C 
binds to calcium, undergoes a conformational change, and activates a target protein.  Instead of 
activating hundreds of different proteins, however, troponin C is only a regulator of troponin I.  
When troponin C binds to calcium, it causes troponin I to no longer inhibit the contraction of 
striated muscle (Kobayashi, Jin, & de Tombe, 2008). 
 Despite their differences in binding partners, troponin C and calmodulin are strikingly 
similar in their amino acid sequence.  Figure 3 is an alignment of the two proteins’ primary 
structure, which reveals that the proteins have 65% sequence identity.  Seeing that the two 
proteins are very similar “cousins” of one another, one basis for the design of a fluorescent 
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calmodulin would be to use fluorescent constructs that have worked in troponin C.  Specifically, 
it has been shown that extrinsic fluorescence can be engineered into troponin C, whereby its 
interaction with troponin I can then be observed.  Unlike CaM, cardiac troponin C natively 
expresses two cysteine residues.  But, those cysteine residues can be converted to serines via 
site-directed mutagenesis.  Then, as discussed earlier, a cysteine can be introduced into the 
protein wherever desired, such as in the place of a threonine or other serine residue.  A troponin 
C with a threonine (T) to cysteine (C) mutation at the 53
rd
 residue (T53C) has been characterized 
previously as an accurate reporter of troponin C behavior (Davis, et al., 2007).  Thus, when 
designing a fluorescent calmodulin, this previous success in engineering a fluorescent troponin C 
serves as an excellent point of reference. 
 Target Peptides.  Any fluorescent calmodulin that we hope to use in the presence of other 
enzymes must be tested to work in a variety of different systems.  Calmodulin binds to entirely 
too many proteins to focus on any one protein as a representative for the whole population.  As 
such, four important enzymes regulated by CaM, chosen somewhat arbitrarily based on their 
current popularity in a variety of fields of research, will be used as tests of the versatility of 
fluorescent CaMs generated for this thesis.  The four CaM-regulated enzymes to be included in 
this study are myosin light chain kinase (MLCK), neural nitric oxide synthase (nNOS), 
calmodulin-dependent kinase II (CKII), and calcineurin (CaN). 
 Myosin Light Chain Kinase.  In humans, there are three forms of MLCK, one for each of 
the three types of muscle tissue.  The most important form of MLCK is expressed in smooth 
muscle (smMLCK).  Since there is no troponin complex in smooth muscle, calcium-dependent 
contraction is regulated by the CaM-smMLCK complex rather than the troponin C-troponin I 
complex.  In smooth muscle, phosphorylation of the myosin light chain by smMLCK enables 
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muscular contraction.  In contrast, the MLCK expressed in cardiac and skeletal muscle does not 
directly allow muscular contraction—troponin C does.  However, MLCK activity in cardiac 
muscle has been identified as an important player in hypertrophic cardiomyopathy (Takashima, 
2009).  The combination of MLCK’s dominant role in the contraction of smooth muscle—which 
regulates arterial tone and thus peripheral resistance to blood flow—with MLCK’s subtle role in 
the regulation of cardiac myosin activation, make it an ideal target for cardiac research. 
 Current MLCK research supports the claim that fluorescent research is a segmented field 
of study.  A research group interested in activation levels of the enzyme chose to place two 
fluorescent markers that flank the CaM-binding region of the MLCK enzyme.  The study was 
interested in following the activation of MLCK, as reported by this two-pronged fluorescent 
probe that senses calmodulin binding, compared to the activation of the myosin regulatory light 
chain (Mizuno, et al., 2008).  Again, we’re confronted with a trend where researchers choose to 
generate their own fluorescent system for a specific enzyme.  And, since CaM regulates 
hundreds of enzymes, potentially hundreds of different fluorescent enzymes would need to be 
generated to measure how CaM interacts with each of those targets.  Alternatively, an 
opportunity exists to attempt to engineer one (or a few) fluorescent calmodulin constructs, which 
could be used across the entire spectrum of CaM-dependent enzyme research.  Having a well 
characterized fluorescent CaM standard would help unify different segments of CaM research, 
rather than forcing each research group to come up with a fluorescent model that suits their 
specific interests. 
 Nitric Oxide Synthase.  Another CaM-regulated enzyme is Nitric Oxide Synthase (NOS).  
Unlike MLCK, which acts as a kinase, NOS is a synthase—and as the name suggests, NOS 
synthesizes nitric oxide (NO).  The action of NO is tissue specific.  As it pertains to 
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cardiovascular physiology, NO is a potent vasodilator.  The action of NO on endothelial cells is a 
hotbed for research involving hypertension, atherosclerosis, arteriostenosis, et cetera (Shaul, 
2002).  By understanding the mechanisms that regulate NOS activity, a cardiac researcher has 
the opportunity to tap into the natural therapeutic power of NO as an antihypertensive agent. 
 A recent study published in Biochemistry pertains closely to the goals of this thesis.  In 
the study, a FRET-based system was used to analyze how calmodulin changes its conformation 
as it binds to different NOS isozymes.  The most accepted current construct for using FRET on 
calmodulin is a two-probe system involving the 34
th
 and 110
th
 residue, both of which are 
threonines.  Conversion of those threonines to cysteines, and subsequent attachment of two 
fluorophores, allows researchers to elucidate how the CaM protein moves in space as it attaches 
to a target—in this case NOS.  The power of this FRET-based approach was validated when it 
was used to predict correctly the conformation of CaM bound to the edema factor of adenylyl 
cyclase, and that prediction was later confirmed by x-ray analysis (Spratt, et al., 2008).  In short, 
FRET systems are proven effective tools for examining the location and conformation of CaM 
molecules. 
 What’s less clearly understood, however, is how these FRET systems affect the kinetics 
or regulatory behavior of small proteins such as CaM.  The 2008 Spratt study referenced earlier 
went to great lengths to make sure that their FRET system was accurately able to report 
quantitatively how the CaM molecule was moving through space as it binds to NOS.  This data is 
absolutely vital for a qualitative understanding of how CaM interacts with targets.  However, one 
shortcoming of this FRET system stems from the dynamic nature of living systems—especially 
cardiac physiology.  Between every heart beat, the cardiac myocyte attempts to sequester 
intracellular calcium, when suddenly a rush of new calcium enters the myocyte, inducing a new 
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contraction, and starting the sequestration process over again.  With calcium concentrations in a 
constant flux, the speed at which calcium-sensitive proteins—CaM, for example—gain and lose 
calcium is pivotal.  Thus, in the quest for a fluorescent calmodulin, the kinetics of that 
fluorescent construct are paramount.  Any fluorescent CaM that you want to use in a system 
relevant to living systems must be able to closely mimic the kinetic behavior of endogenous 
proteins. 
 Calcineurin.  The third CaM-binding protein to be included in this thesis is calcineurin 
(CaN).  Unlike MLCK, which is a kinase, CaN is a phosphatase.  By removing a phosphoryl 
group on nuclear factor of activated T cells (NFAT)—a transcription factor—calcineurin is able 
to regulate gene transcription indirectly.  The role of calcineurin in immunology is much better 
understood than its role in cardiac physiology.  When a T cell is stimulated to differentiate into a 
helper T cell, a signal transduction pathway carries that differentiation message from a receptor 
on the cell surface to the nucleus.  Calcineurin is a major checkpoint in that pathway, and only 
through CaM-dependent activation of CaN can that T cell differentiate to become whatever type 
of T cell it needs to be.  Immunosuppressant drugs that suppress CaN activity, such as 
cyclosporin, have been around for decades (Liu, 1993). 
 About a decade ago, the Molkentin lab in Cincinnati made a remarkable and simple 
discovery about CaN.  They found that if you predisposed a mouse to cardiac hypertrophy, but 
blocked the action of CaN by cyclosporin, that mouse would not develop cardiac hypertrophy 
(Sussman, et al., 1998).  Subsequent analysis, however, would demonstrate that cardiac 
hypertrophy could not be so easily prevented in humans with cyclosporin therapy, due to such 
boundaries as the nephrotoxicity of cyclosporin (Leinwand, 2001).  What was made clear, 
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however, was that some facet of cardiac hypertrophy was under regulation by the CaN-NFAT 
pathway, and should be considered a target for cardiac research.   
 Recent research in the field has been targeted at elucidating the exact role of CaN in 
cardiac physiology.  Cyclosporin therapies are frequently used in tandem with antihypertensive 
drugs such as calcium channel blockers or ACE inhibitors.  Both the immunosuppressant and 
antihypertensive drugs have the effect of CaN suppression, which has led researchers to 
investigate how the widespread silencing of CaN activity affects cardiac health.  Tests so far 
have been fairly inconclusive (Zhang, Zhu, & Zhang, 2009).  Furthermore, it is also of special 
interest to see how the constantly changing calcium concentration in the heart affects CaN 
activity in comparison to the relatively static calcium environment of other cell types (Houser & 
Molkentin, 2008).  By the same vein, this thesis is interested in embracing the calcium 
fluctuations of the heart as a pivotal component of cardiac research. 
 Calmodulin-dependent kinase II.  The fourth and final CaM-regulated enzyme to be used 
for this thesis is CKII.  CKII is a kinase that doesn’t just phosphorylate one specific target, it has 
an abundance of possible targets, just like CaM does.  About a decade ago, it was observed that 
CKII is overexpressed in late-stage cardiac disease (Hoch, Meyer, Hetzer, Krause, & 
Karczewski, 1999).  Since then, the field of CKII research has grown tremendously, with 
different researchers finding different pathways regulated by CKII to focus on.  The number of 
CKII articles published between 2001 and 2006 doubles that of the previous five years (Maier, 
2009). 
 CKII is a particularly important player in cardiac physiology because of its role in the 
regulation of different calcium handling processes.  CKII phosphorylates ryanodine receptors, 
phospholamban, and L-type calcium channels, all of which play pivotal roles in the management 
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of intracellular calcium levels and excitation-contraction coupling (Maier & Bers, 2002).  It’s 
particularly interesting that CKII regulates a great number of calcium handling pathways, and 
CKII is also itself regulated by calcium levels. 
 Objectives 
 As evidenced by the litany of different techniques being employed to follow CaM 
behavior using fluorescence, CaM research is an unnecessarily segregated field of study.  
Researchers develop new fluorescent systems each time they want to answer a specific question, 
a trend that leads to extra expenses and perhaps overspecialized model systems.  Despite the 
popularity of fluorescence as a tool, no one is taking a moment to develop the best tool possible 
for the job, and sharing that tool with others.  Most fluorescent techniques are either assumed to 
work, or are too highly specialized for one research question to be at all beneficial to other 
researchers.  As such, it has become apparent that CaM researchers would stand to benefit from 
someone taking the time to engineer a fluorescent CaM that encapsulates as many possible 
segments of the CaM research field with one fluorescence approach.  A fluorescent calmodulin 
that has diverse utility would give CaM researchers a common tool that could facilitate crosstalk 
between different segments of study, as well as different strata of complexity within any one 
segment of study. 
 However, it would also be naïve to assume that any one panacea exists to completely 
unify CaM researchers.  FRET approaches are uniquely powerful tools for measuring spatial 
arrangements, and I imagine that T34C/T110C dual-probe FRET systems will continue to 
dominate as the standard for modeling CaM movements.  Furthermore, biophysicists that model 
the behavior of single CaM molecules will likely be completely disinterested in a CaM that has a 
prosthetic fluorophore attached; they can get along just fine relying on intrinsic fluorescence.  In 
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other cases, a fluorescently labeled CaM protein won’t give the type of information a biochemist 
may need if he’s studying a CaM target protein such as MLCK.  The niche that needs filled is 
somewhere between all these strategies—there is a need for a fluorescent CaM that is sensitive to 
CaM’s ability to bind calcium and CaM’s ability to bind with target proteins.  Researchers, 
whether they be interested in NOS, MLCK, or otherwise, would benefit from being able to turn 
to one fluorescent CaM specifically engineered to behave like WT CaM.  They could employ 
this protein to observe how CaM regulates their enzyme of interest, and be confident that this 
fluorescent CaM is a reliable representation of the behavior of the wild type protein.  Eventually, 
hundreds of different segments of study could potentially benefit from the development and 
characterization such a calmodulin. 
 Since this fluorescent calmodulin is being developed within the walls of a cardiac 
physiology lab, the most immediate goal is to design and test a fluorescent calmodulin with a 
smattering of different enzymes important in cardiac physiology.  Specifically, the fluorescent 
calmodulin will be studied in the presence of peptide fragments of the four enzymes discussed 
earlier in this thesis (MLCK, NOS, CKII, CaN).  The best fluorescent calmodulin will be the 
protein that behaves most similarly to the wild type protein in the presence of the peptides. 
 The kinetic behavior of the engineered CaMs will be measured, fit mathematically, and 
compared to one another via statistical analysis.  The kinetic behavior of a fluorescent CaM must 
not be significantly different from the wild type in order to be considered successful.  The 
simplest and ideal result would be one fluorescent CaM that behaves statistically similar to the 
WT in the presence of all four peptides.  Other results—where a fluorescent CaM behaves like 
the WT in the presence of one peptide but not others—will have to be interpreted more carefully. 
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Chapter II 
Methodology 
 The basic techniques to be used to generate fluorescent CaM proteins are, for the most 
part, well understood.  An overview of the methodological strategy follows, and subsequent 
subsections detail each individual step.  Please note that specific buffer composition and other 
cumbersome language have been omitted from the text of this thesis for the sake of readability, 
with a few exceptions.  A copy of the protocols used for this thesis have been included at the end 
of the report should any questions arise. 
 The first step to creating a calmodulin mutant is to choose which genetic mutations 
should be generated.  RasWin was employed as a viewer of the crystal structures for calmodulin-
peptide complexes, such as CaM-RS20 complex and CaM-NOS complex.  Threonine residues in 
the N-domain that appeared to orient themselves away from the interior of the protein were 
identified as candidates for mutation (T5, T34).  A third mutation (T44C) was made based on a 
successful fluorescent construct from troponin C.  Mutations were made to a pET3d plasmid 
containing the rat CaM gene via primer-based PCR and site-directed mutagenesis using the 
Stratagene QuikChange site-directed mutagenesis kit.  After confirming the mutations by 
sequence analysis, mutant plasmids were transformed into BL21(DE3)pLysS Escherichia Coli 
cells and induced to express the introduced CaM gene.  Cells containing the mutant CaM gene 
were then lysed by sonication, and the insoluble cellular elements were removed by 
centrifugation.  Subsequent treatment with ammonium sulfate precipitated out a few water-
soluble proteins in the mixture, which were discarded as waste.  The remaining solution, which 
contained CaM, was purified using column chromatography on a phenylsepharose column, 
yielding highly purified calmodulin. 
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 A fraction of the purified calmodulin was reacted with [2 - (4 '- (iodoacetamido) anilino) 
naphthalene -6 - sulfonic acid] (IAANS).  The concentration of the labeled CaM protein was 
determined by spectrophotometry.  In terms of data collection, the calcium dissociation rates of 
the CaM protein were determined using an Applied Photophysics Ltd. model SX.18 MV 
stopped-flow instrument with a dead time of 1.4 ms at 20 °C.  Since the WT protein could not be 
labeled with IAANS, its calcium dissociation rate was measured with Quin-2, a fluorescent 
calcium chelator.  A program that uses the Levenberg-Marquardt algorithm was used to fit the 
data to a double exponential curve.  Calcium dissociation rates were compared to one another via 
one-way ANOVA, with p values <0.05 taken as significant. 
 CaM mutant design and creation.  Crystal structures for the four CaM complexes to be 
studied were obtained from the Protein Data Bank, which can be found at rscb.org.  The four 
models specifically used were 1QTX (RS20), 2R28 (CaN), 1MXE (CKII), and 1NIW (NOS) 
[See Figure 4].  The threonine residues in the N-domain of CaM were examined in each of the 
four crystal structures.  T5 and T34 were chosen as potential candidates for mutation based on 
their R group’s orientation away from the interior of the complex.  It seems logical that if the 
probe is engineered to stick out away from the protein that the core functions of the protein will 
not be sterically inhibited by the presence of the fluorophore.  The T44 residue was identified as 
a candidate for mutation not based on crystallographic analysis, but based on the success of a 
homologous mutation that provided a successful fluorescent construct in troponin C.  Since CaM 
and troponin C share 65% of their sequence, it seems worthwhile to attempt to mimic the success 
of the T53C-IAANS fluorescent construct of troponin C (Davis, et al., 2007). 
 The rat CaM gene, whose primary structure is completely identical to human CaM, was 
already available in my lab from previous work with CaM systems.  The pET3d plasmid that 
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contains the CaM gene also codes for ampicillin resistance, has a lac operon, as well as other 
functionally important properties.  Mutations to the CaM gene on the plasmid were accomplished 
using primer-based PCR, in which the plasmid is copied repeatedly, using a primer containing a 
replacement sequence that contains a desired mutation, such as T5C.  The PCR reaction 
preferentially copies the mutant protein DNA, due to its tremendous excess in the solution.  
Leftover parent DNA was removed from solution by cleavage with the DPN1 enzyme that 
digests methylated DNA.  The result is a concentrated stock of CaM plasmid with the mutant 
CaM in the place of WT CaM.  The plasmid was repaired when it is transformed into XL1-Blue 
E. Coli cells, whereby the cell machinery ligates the synthetic plasmid from the PCR reaction 
back into circular plasmid DNA.  This circular plasmid DNA was then extracted from the XL1-
Blue cells using a Quiagen Mini-Prep DNA extraction kit.  The success of the mutation was 
verified by sequence analysis, which for this research was conducted by the Plant Microbe 
Genomics Facility at Ohio State. 
 Protein Expression and Purification.  Once the sequence of our mutant plasmids was 
confirmed by sequence analysis, the mutant plasmids were transfected into BL21(DE3)pLysS E. 
coli cells.  The BL21(DE3)pLysS strain of E. coli is designed to facilitate expression of our 
mutant DNA contained in the mutant plasmid.  BL21(DE3)pLysS cells were brought up to a 1L 
culture in LB medium, and the cells were made to begin expressing CaM by addition of a protein 
called IPTG.  IPTG is a transcription factor that turns on the lac operon, which is the upstream 
promoter of the CaM gene in this plasmid system.  Induction by IPTG was allowed to progress 
for three hours, after which the cells were extracted from the media via centrifugation.  The cells 
were resuspended in a solution of protease inhibitors, and the cell membranes were lysed via 
sonication.  Insoluble organelles and cytosolic elements were removed via centrifugation.  The 
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resultant solution is a concoction of numerous soluble proteins.  Since CaM is resistant to 
precipitation by ammonium sulfate, a fraction of the protein contamination in the solution was 
precipitated out by addition of ammonium sulfate.  Precipitated proteins were again removed by 
centrifugation.  The leftover solution was then given a large dose of calcium, and then loaded 
onto a phenylsepharose column.  The calcium serves to saturate calmodulin, which exposes very 
hydrophobic regions within the CaM molecule, allowing it to stick to the phenylsepharose 
column.  After washing the column, CaM is eluted with the addition of EGTA, which chelates 
calcium away from CaM, hiding CaM’s hydrophobic regions, and causing CaM to elute from the 
hyrdrophobic column. 
 Protein labeling.  Approximately half of the purified CaM was labeled with the chosen 
fluorophore—IAANS.  IAANS reacts selectively to the thiol group on the cysteine that was 
engineered into the CaM sequence.  CaM was treated with dithiothreitol (DTT) to reduce its thiol 
group to ensure proper reactivity with the IAANS probe.  DTT was then dialyzed out of the 
protein solution, and urea was dialyzed into the solution to denature the CaM protein.  IAANS 
was dissolved in dimethylformamide (DMF) and added to the CaM protein in five-fold excess to 
ensure maximal contact between the protein and the fluorophore.  The reaction proceeded for 
two hours at room temperature.  Excess fluorophore and urea is removed from the protein 
solution by extensive dialysis.  The result is a solution of protein labeled at the mutant cysteine 
residue with the IAANS probe. 
 Kinetic Characterization of Calmodulin.  The calcium dissociation rates (Koff) of the 
three Calmodulin-IAANS fluorescent mutants were determined by stopped-flow 
spectrophotometry.  The exact apparatus used was an Applied Photophysics Ltd. model SX.18 
MV stopped-flow instrument with a dead time of 1.4 ms.  This experimental design relies on two 
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different methods for measuring fluorescence.  For our experimental group—the engineered 
fluorescent calmodulins—IAANS fluorescence was measured by exciting the sample at 330 nm 
and emission was collected with a photomultiplier tube fitted with a 420-470 nm filter.  For the 
control experiments—using WT CaM—Quin-2 was used as the source of fluorescence.  Quin-2 
was excited at 330 nm as well, and its emission was filtered through a 510 nm broad band pass 
interference filter.  A program that uses the Levenberg-Marquardt algorithm was used to fit the 
data to a double exponential curve, which yields a rate constant for the calcium dissociation 
event we were using.  The buffer composition for all kinetic experiments is as follows: 10 mM 
MOPS, 150 mM KCl, 3 mM Mg
2+
, 1 mM DTT, pH7.0.  The MOPS is a pH buffering reagent, 
the KCl, Mg
2+
, and H
+
 concentration mimic intracellular ion concentrations, and DTT is used as 
a reducing agent to protect against protein oxidation.  All kinetic experiments were conducted at 
20 °C. 
Experimental Design 
 One of the most important aspects of this study is establishing an experimental design 
that allows us to answer a few basic questions.  For one, how can we be sure that our designed 
fluorescent constructs behave statistically similar to the WT protein?  And, secondly, can we 
determine where in the manufacturing process any proteins that don’t behave like the WT protein 
lose their WT-like characteristics?  Do they become different after the genetic change we are 
making within the protein (the T to C mutation) or after we covalently link them to the 
fluorophore? 
There are multiple ways for us to answer whether or not the engineered proteins behave 
like the WT protein.  Calmodulin has two basic functions.  One, it binds to and dissociates from 
calcium ions.  Secondly, CaM binds to and dissociates from target proteins.  Both phenomena 
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can be tracked via the fluorophore we’ve introduced into the protein.  However, designing a 
control experiment for calcium binding is much more clear-cut than designing a control 
experiment for protein-protein binding.  Ultimately, we need to measure how well our 
engineered calmodulin mutants behave compared to the WT protein. 
 Furthermore, there are multiple methods to examine the behavior of a protein.  Two basic 
approaches to a calcium-binding protein such as calmodulin are steady-state experiments and 
kinetic experiments.  Steady-state experiments are usually titrations, in which calcium or a target 
protein is titrated into a solution of calmodulin, and fluorescence is used to determine the 
concentration at which calmodulin is able to bind to either calcium or the target protein.  
Alternatively, kinetic experiments determine the rate at which these binding or dissociation 
events occur.  So, instead of determining the effective concentration at which a target protein is 
able to bind with CaM, a kinetic experiment tells you how fast that reaction occurs.  Both are 
important pictures of CaM function, and good indicators to use when determining whether or not 
a mutant protein behaves like the WT variety. 
 When working with an unknown, new fluorescent construct, it’s beneficial to use one 
technique to build intuition about the other technique.  That is, the fluorescent activity during 
kinetic experiments should relate to the fluorescent activity of steady-state experiments.  For 
example, when a kinetic experiment is conducted in which CaM loses calcium over time, and 
also loses fluorescence over time, one could reason that high fluorescence correlates with large 
amounts of calcium bound to the protein.  Thus, when that same fluorescent protein is used in a 
steady state experiment, one would expect for the fluorescence of the CaM solution to increase 
as calcium is titrated into the reaction mixture. 
Engineering a Fluorescent Calmodulin      26 
 
 This, unfortunately, is an oversimplification of the reality of CaM behavior.  CaM has 
four calcium binding loops, two in each domain of the protein.  Past experiments have 
demonstrated that the C and N-terminal halves of the protein have different calcium sensitivities, 
and thus different kinetic behavior (VanScyoc, et al., 2002).  In addition to this, the two domains 
of calmodulin also have different effects on the fluorescent behavior of the protein.  Preliminary 
experiments revealed the following trends regarding CaM labeled with IAANS in the N-domain. 
i. The N-terminal domain of calmodulin has a low sensitivity to calcium when 
compared to the C-terminal domain.  This makes the N-terminal domain lose 
calcium much faster than the C domain.  The N-terminal domain has low 
fluorescence when calcium-bound, and high fluorescence when calcium-free. 
ii. The C-terminal domain has higher calcium affinity than the N-terminal domain.  
C-terminal kinetics are much slower than N-terminal kinetics.  C-terminal 
fluorescence is high when it is bound to calcium, and low when it is not. 
The result of these two observations makes titrations very difficult.  As calcium is added 
to any of our three engineered CaM proteins, the fluorescence signal at first increases as the C-
terminal domain grabs calcium.  Further calcium additions cause the fluorescence signal to 
decrease, which is a result of the N terminal domain grabbing calcium.  Biphasic titrations such 
as this are very difficult to characterize, and efforts to study the steady-state behavior of the 
IAANS labeled CaM mutants are ongoing.  Thus, for the constraints of this thesis, the more 
easily interpreted kinetic data are presented as the representative for CaM function. 
This, however, plays well into the context of the research.  We are most interested in how 
we can use these designed fluorescent calmodulins to gain a better understanding of how 
calmodulin regulates a spectrum of different pathways that relate to cardiac function.  We also 
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know that calcium concentrations of cardiac myocytes are in constant flux.  With the constant 
calcium transients of cardiac tissues, the most important characteristic for these engineered 
fluorescent CaM proteins to retain is their kinetic properties. 
 Another point we need to consider, before we delve into the specifics of what 
experiments will be performed, is the duality between the N and C terminal sides of the protein, 
their role in regulation of cardiac systems, and what that means for engineered fluorescence.  It 
has been shown that the concentration of CaM freely floating around in the cytosol of cardiac 
myocytes is on the order of 50-75 nM.  This, surprisingly, is only 1% of the total CaM in a given 
cardiac myocyte.  This research suggests that CaM is almost always active and able to bind to 
target proteins (Wu & Bers, 2007).  There are several reasons why CaM could be almost always 
bound to target proteins.  For one, the classical model that CaM must first bind calcium and then 
bind a target protein could be flawed.  Proteins with high affinity for CaM are probably binding 
to the CaM protein even at resting calcium concentrations.  Another implication of this research 
is that the C domain—the more sensitive domain to calcium—could be bound with calcium even 
at resting calcium concentrations, which partially activates CaM and allows it to bind with 
targets.  Calcium fluctuations, from that point, would be targeted at the N-domain of the protein, 
which would bind with calcium and activate whatever protein CaM was already bound to. 
While these non-classical mechanisms of CaM activation have yet to be fully understood, 
what is clear is that the N-terminal domain of CaM has a sensitivity to calcium that is more likely 
to be directly affected by rising and falling calcium transients in a beating myocyte.  As such, it 
is a greater priority to understand what is happening in the N-terminal domain of CaM moreso 
than the C-terminal domain, since the sensitivity of the N-terminal domain seems to have a more 
direct role in the regulation of CaM function.  This line of reasoning is the basis for why the 
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three fluorescent mutants in this study were located in the N-terminal domain, and why our 
experimental design will also focus on the N-terminal domain kinetics. 
Selection of fluorophore.  The engineering strategy being employed in this study—where 
one prosthetic group is being attached to a cysteine residue—limits which fluorophores can be 
used.  The Invitrogen Molecular Probes Handbook details a family of different cysteine-reactive 
environmentally sensitive probes that could be used in this experiment.  Each probe has a 
molecular weight on par with a tryptophan residue.  Preliminary research for this study identified 
that IAANS gave the best signal to noise ratio of the fluorophores available in our lab, and so it 
was used as the fluorophore of choice when labeling the three mutation candidates.  Consult 
figure 5 for the structure of IAANS. 
Experimental Protocol.  Finally, the experiments themselves.  The experimental group—
T5C IAANS, T34C IAANS, and T44C IAANS—will all be analyzed in the stopped-flow 
spectrophotometer.  Figure 6 is a simple schematic diagram of a stopped-flow apparatus.  
Measurements of calcium dissociation rates will be achieved by observation of the rapid mixing 
of two solutions.  The first solution will contain a buffer, an IAANS-labeled CaM protein, a 
peptide fragment of one of the four proteins we’ve chosen (NOS, CaN, CKII, RS20), and 
calcium.  Imagine this syringe containing essentially any of the four complexes depicted in 
figure 4.  The second syringe will simply contain the same buffer and a tremendous excess of 
EGTA, a calcium chelator.  EGTA is able to chelate calcium instantaneously as CaM dissociates 
from it, and since an equilibrium exists between calcium-bound CaM and calcium-free CaM, 
EGTA sequesters all calcium that CaM dissociates from for even the slightest amount of time. 
The kinetic characteristics of the WT CaM protein, our control, will be measured using a 
fluorescent cousin of EGTA called Quin-2.  Quin-2 has widely been used as a fluorescent stand-
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in for EGTA (Tikunova & Davis, 2004).  Just like the previous experiment, WT calcium-bound 
CaM bound to a peptide will be mixed with a calcium chelator.  In this control experiment, 
however, it is not the CaM protein itself that is fluorescing, but the Quin-2 chelator.  The rate of 
Quin-2 fluorescence change is equal to the rate at which CaM loses calcium.  This Quin-2 
technique will also be employed to analyze whether or not the genetic mutation from threonine 
to cysteine has any effect on calcium dissociation rates, for the stock of proteins that have 
undergone mutation but have not been labeled with IAANS. 
Chapter III 
Results 
 The results for our kinetic characterization of the calmodulin mutants are displayed in 
figures 7 through 10.  The difference between these figures is the peptide used with CaM.  The 
colored traces represent the time course in which CaM transitioned from its initial fluorescence 
before mixing with EGTA or Quin-2, to the point where the experimental solution reached its 
maximal fluorescence.  This fluorescent plateau is interpreted to represent the point at which all 
calcium had been lost from the N-terminal domain of CaM. 
 A statistical analysis of these four figures can be found in tables 1 through 4.  The n 
values represent how many total traces were averaged to find the average calcium dissociation 
rate Koff.  A one-way ANOVA test was employed to test for significant differences from the WT.  
For the purposes of this study, any fluorescent construct that behaves significantly different from 
the WT is unsuccessful, at least in that particular peptide system. 
 According to the statistical analysis, the T44C construct was significantly different (p < 
0.05) from the WT in each of the four peptide systems used.  The T5C construct behaved 
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significantly different from the WT only in the CKII system.  The T34C construct behaved 
significantly different from the WT in the CaN system. 
 A qualitative analysis of the difference between the T5C and T44C CaM is available in 
figure 11.  Both of these traces compare three steps along the process.  First, a WT Quin-2 trace 
is shown.  The next trace is a representative of the protein after the T to C genetic mutation has 
been made, but before the protein has been labeled with IAANS.  The last trace is then the 
calcium dissociation rate of the protein with IAANS.  This data suggests that the genetic 
mutation and the fluorescent labeling of T5C IAANS affect the calcium dissociation kinetics in 
equal but opposite ways.  However, the genetic mutation and labeling of T44C CaM both sum to 
create a much faster CaM overall in terms of N-terminal calcium kinetics. 
Conclusions 
 Although nothing in the statistical analysis here allows me to say what is statistically 
similar to the WT probe, what can be determined is which probes were most consistently not 
significantly different.  Both T5C and T34C showed fairly equal success, both being found to be 
not significantly different from the WT in three of the four peptides used.  However, the T5C 
fluorescent construct demonstrates a superior signal-to-noise ratio to the T34C fluorescent 
construct.  Specifically, the width of the data traces are noticeably narrower for T5C than T34C.  
Based on that observation, I would chose to use the T5C probe over the T34C probe in systems 
where both were shown to not behave significantly different from the wild-type. 
 What’s particularly interesting is that the three fluorescent constructs seemed to deviate 
most strongly from the WT in terms of average Koff in the system with a non-classical CaM-
peptide association pattern, the CaN system.  As shown in figure 4, CaM binds to CaN in a 2:2 
antiparallel arrangement in the best available crystal structures, whereas the other binding 
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patterns shown in figure 4 resemble the classical arrangement of calmodulin wrapping around a 
target peptide.  It is unclear as to whether this 2:2 binding arrangement is specific to the peptide 
subunits being employed in this study, or if this 2:2 binding arrangement is preserved in the 
intact CaN holoenzyme. 
 To be able to measure these same calcium dissociation rates in the presence of intact 
holoenzymes would be an exciting next step for this research.  These four peptide constructs 
have served as a proof of principle that CaM calcium dissociation rates can still be reliably 
measured in the presence of CaM targets.  What remains unclear is whether or not the constructs 
created to work with these peptides will also work with the entire enzyme.  It is very possible to 
imagine that distal domains of the target enzymes might sterically interact with the IAANS 
fluorophore and that fluorophore will no longer properly report the true calcium dissociation rate 
of the CaM protein.  It is very exciting, however, to imagine the best case scenario—where the 
T5C or T34C IAANS fluorescent CaM constructs continue to reliably report calcium 
dissociation rates in the presence of whole enzymes. 
 However, for the time being, the model system we’ve generated has shown promise.  At 
the first trial of their reliability, the T5C IAANS and T34C IAANS fluorescent CaM constructs 
have been shown to reliably report calcium dissociation rates in at least a few peptide systems.  
In the future, these fluorescent models will be further characterized, and perhaps employed as a 
common tool for a diverse population of CaM researchers.  At the very least, we’ve taken the 
first steps to ensure that our CaM fluorescent system, a carefully selected reductionism of the 
overwhelmingly complex landscape of cardiac research, generates reliable data that we can 
confidently share with the scientific community. 
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Appendix A 
Calmodulin Purification Protocol 
1. Transform the CaM plasmid into BL21 bacteria. 
2. Grow transformed BL21 bacteria in 1 L flasks of LB media + Amp, until OD600 is 0.6-0.8 
3. Add 0.4 mM IPTG  (1 mL of a .4 M stock) 
4. Grow cells with IPTG for another 3-4 hours 
5. Spin cells for 15 min @ 8,000 rpm, 10 deg. C 
6. Resuspend cells in 30mL resuspension buffer for every 1 L of starting volume 
a. Resuspension buffer – 50 mM Tris, 2mM EDTA, 1mM DTT, 1mM PMSF, pH 7.5 
7. Sonicate cells on ice – Output 6, duty cycle 60%, 6 times for 2 minutes each. 
8. Spin solution for 30 minutes @ 11,500 rpm and 4 deg. C. 
9. Collect supernatant 
10. Add slowly 27g of ammonium sulfate per 100 mL (45% saturation) and let stir for 1 hr.  Perform 
this step while stirring in the cold room. 
11. Spin solution for 30 minutes @ 11,500 rpm and 4 deg. C  (keep supernatant) 
12. Equilibrate phenylsepharose Cl-4B column (~15 mL resin) with buffer A. 
a. Buffer A – 50 mM Tris, 1mM DTT, 500 µM Ca2+, pH 7.5 
b. Note: See Phenylsepharose Column Prep Protocol if necessary. 
13. Add 5mM Ca2+ to the supernatant from step 11, and load onto column. 
14. Wash column with buffer A until OD280 of flow through falls below 0.03. 
15. Wash column with buffer B until OD280 of flow through falls below 0.02. 
a. Buffer B – 50 mM Tris, 0.5 M NaCl, 500 µM CaCl2, 1mM DTT, pH 7.5 
16. Elute with buffer C 
a. Buffer C – 50 mM Tris, 0.15 M NaCl, 5 mM EDTA, 1mM DTT, pH 7.5 
17. Collect 5 mL fractions (typically comes off between 3rd to 6th fraction) 
18. Measure OD280. 
a. wtCaM extinction coefficient @280 is 3140 
19. Place pulled fractions into dialysis 
20. Run on gel 
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Appendix B 
 
Protein Labeling with IAANS protocol 
 
1. Place proteins to be dialyzed into 4 degree fridge to allow thaw time. 
2. Reduce proteins in 5mM DTT for a few hours before step 3. 
3. Dialyze 100 M of protein (probably 3-5 mL of fraction with the highest OD) against 2 L urea 
buffer overnight. 
a. Urea buffer – 50 mM Tris, 90 mM KCl, 1 mM EGTA, 6 M Urea, pH 7.5 
4. Check OD280 of dialyzed protein and determine concentration 
a.  CaM Extinction coefficient = 2560  (SCaM 1 is 1280) 
5. Make 10 mM IAANS in dimethylformamide (DMF)  (0.5 mg/ 100 L) 
a. Make a fresh stock big enough for the proteins that need labeled that day. 
i. The concentration of added label should be 5x the protein conc. 
ii. Eg. 150 M protein needs 750 M label 
6. Add IAANS slowly, dropwise, and shake for 5-8 hours at 4 C.  (parafilm lids) 
a. Alternatively, shake for 2 hours at RT. 
7. Add 2 mM DTT to stop the reaction. 
8. Dialyze overnight against urea buffer. 
9. Dialyze against 3 changes of 4 L of: 
a. 10 mM MOPS, 90 mM KCl, pH 7.0 
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Appendix C 
Reaction Mixtures for Stopped Flow Spectrophotometry 
IAANS Experiments 
Syringe A Syringe B 
0.5 μM CaM 
3 μM peptide 
200 μM Ca2+ 
Buffer 
10 mM EGTA 
Buffer 
 
 
 
 
Quin-2 Experiments 
Syringe A Syringe B 
3 μM CaM 
20 μM peptide 
20 μM Ca2+ 
Buffer 
150 μM Quin-2 
Buffer 
 
Note: See Figure 6 for a schematic diagram of stopped flow spectrophotometry and how syringe 
A and B interact. 
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Table 1 
Statistical Analysis of RS20 System 
Protein  n  Avg. Koff (/s) p  
WT  15  7.8 ± 0.20 
 
T44C  15  24.4 ± 2.95 0.000  
T34C  20  6.5 ± 0.21 0.207*  
T5C  20  8.5 ± 0.31 0.561* 
 
Note: *p > 0.05 
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Table 2 
Statistical Analysis of CaN System 
Protein n Avg Koff (/s) p 
WT 15 12.0 ± 0.85 
 
T44C 15 28.6 ± 3.01 0.000 
T34C 20 17.9 ± 0.72 0.0158 
T5C 20 15.8 ± 1.11 0.0799* 
 
Note: *p > 0.05 
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Table 3 
Statistical Analysis of NOS System 
Protein n Avg. Koff (/s) p 
WT 15 19.6 ±1.85 
 
T44C 15 44.8 ± 4.56 0.000 
T34C 20 26.3 ± 2.61 0.0632* 
T5C 20 16.5 ± 1.68 0.233* 
 
Note: *p > 0.05 
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Table 4 
Statistical Analysis of CKII System 
Protein n Avg Koff (/s) p 
WT 15 12.6 ± 0.52 
 
T44C 15 29.0 ± 2.68 0.000 
T34C 20 12.0 ± 0.95 0.736* 
T5C 20 9.0 ± 0.48 0.0227 
 
Note: *p > 0.05 
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Figure Captions 
Figure 1.  The Crystal structure of CaM protein represented in ribbon form.  Black orbs represent 
calcium ions (Rupp, Marshak, & Parkin, 1996).  The zig-zag portion at the bottom of the 
diagram represents a tail of the protein that did not resolve clearly in the crystal structure. 
Figure 2.  The primary structure of calmodulin protein is shown at the top, with mutated residues 
colored in cyan, yellow, and magenta. The protein structure below that indicates the location of 
those three residues within the protein three-dimensional structure.  The yellow, cyan, and 
magenta color scheme here is maintained throughout the report.  The colors alternate between 
black and red every ten residues to assist in counting. 
Figure 3.  Alignment of human calmodulin (hCaM) with cardiac troponin C (cTnC).  Residues 
with >90% consensus are shown in green, and mismatched residues are shown in black and red.  
97 of the 149 overlapping residues are high consensus (identical or very functionally similar), 
indicating that these two proteins are 65% identical. 
Figure 4.  Comparison of the crystal structures of Calmodulin with each of the four peptides 
used in this study.  The crystal structures used were models 1QTX (RS20), 2R28 (CaN), 1MXE 
(CKII), and 1NIW (NOS).  Each of these models is available from the protein data bank, 
rscb.org.  The CaN complex has so far only been simplified to the 2:2 binding scheme shown in 
the diagram.  In all cases, the peptide is shown in red, and CaM  is shown in navy.  The 
additional green protein in the CaN structure is another CaM molecule, arranged in an 
antiparallel relationship with the navy colored CaM molecule. 
Figure 5.  Structure of the IAANS probe (Invitrogen 2009). 
Figure 6.  Schematic Diagram of a stopped-flow apparatus (Lehrer 2004). 
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Figure 7-10.  Real data is shown whenever possible.  All traces shown are a representative of the 
average, rather than an aggregate sum.  Fit curves were used where data would obscure other 
data from view, or when the signal-to-noise ratio of that data made its trends not immediately 
visible.  Most commonly, those fit curves were used to display the data for the T5C and T34C 
constructs, and the figure legends indicate which curves are fits. 
Figure 11.  Comparison of the phases of T5C construct generation to the phases of T44C 
construct generation.  Data was collected using the RS-20 peptide system, such as that used for 
the experiment shown in figure 7. 
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Figure 1 
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Figure 2 
MADQLTEEQIAEFKEAFSLFDKDGDGTITTKELGTVMRSLGQNPTEAELQ 
DMINEVDADGNGTIDFPEFLTMMARKMKDTDSEEEIREAFRVFDKDGNGY 
ISAAELRHVMTNLGEKLTDEEVDEMIREADIDGDGQVNYEEFVQMMTAK 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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Figure 7 
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Figure 8 
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Figure 9 
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Figure 10 
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Figure 11 
 
 
